13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001475373
Total reported value
$461.0M
$461.0M
29 檔
27.8%
The Q3 2024 SEC filing reveals that Sector Gamma As held a total portfolio value of $461.0M, covering 29 public equity positions.
In Q3 2024, Sector Gamma As displayed an active expansion posture, initiating 4 new positions and adding to 15 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including BMY, MDT, GILD) accounted for 27.8% of total reported equity market value during Q3 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 9.45% | -2.78% | +12.52% | |
| 2 | MDT | Medtronic plc | Stock-Healthcare | 9.15% | +0.24% | +26.43% | |
| 3 | GILD | Gilead Sciences Inc | Stock-Healthcare | 7.36% | -1.75% | EXIT | |
| 4 | PFE | Pfizer Inc | Stock-Healthcare | 7.20% | -1.99% | -8.38% | |
| 5 | CVS | Cvs Health CORP | Stock-Healthcare | 5.76% | +1.19% | +37.27% | |
| 6 | BDX | Becton Dickinson And Co | Stock-Healthcare | 5.65% | -0.01% | — | |
| 7 | INCY | Incyte CORP | Stock-Healthcare | 5.19% | -0.26% | +27.35% | |
| 8 | BAX | Baxter International Inc | Stock-Healthcare | 4.44% | — | +48.08% | |
| 9 | ELV | Elevance Health Inc | Stock-Healthcare | 4.15% | +0.69% | +8.24% | |
| 10 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 4.06% | +0.46% | +200.48% | |
| 11 | CAH | Cardinal Health Inc | Stock-Healthcare | 3.93% | -0.64% | +9.34% | |
| 12 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 3.47% | -0.67% | +24.71% | |
| 13 | BRKR | Bruker CORP | Stock-Healthcare | 3.33% | -0.18% | +37.67% | |
| 14 | QGEN | Qiagen N.V. | Stock-Healthcare | 3.09% | — | +167.27% | |
| 15 | GEHC | GE Healthcare Technology | Stock-Healthcare | 3.04% | +0.77% | +2.60% | |
| 16 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.56% | +0.26% | +24.02% | |
| 17 | CNC | Centene CORP | Stock-Healthcare | 2.17% | +1.00% | +111.11% | |
| 18 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.13% | +0.05% | +53.50% | |
| 19 | BIIB | Biogen Inc | Stock-Healthcare | 2.07% | -1.36% | -20.05% | |
| 20 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 1.71% | +0.56% | — | |
| 21 | AMGN | Amgen Inc | Stock-Healthcare | 1.56% | -1.86% | -46.67% | |
| 22 | BNTX | Biontech Se-adr | Stock-Other | 1.44% | — | — | |
| 23 | THC | Tenet Healthcare CORP | Stock-Healthcare | 1.33% | — | -50.13% | |
| 24 | UHS | Universal Health Services-b | Stock-Healthcare | 1.22% | — | -49.64% | |
| 25 | HUM | Humana Inc | Stock-Healthcare | 1.15% | -0.79% | EXIT | |
| 26 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 1.06% | -1.67% | EXIT | |
| 27 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.92% | — | -44.27% | |
| 28 | ALKS | Alkermes plc | Stock-Healthcare | 0.85% | — | -48.45% | |
| 29 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.57% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BDX | Becton Dickinson And Co | +5.7% | NEW | New buy |
| 2 | BMRN | Biomarin Pharmaceutical Inc | +2.1% | +200.48% | Add |
| 3 | QGEN | Qiagen N.V. | +1.8% | +167.27% | Add |
| 4 | BNTX | Biontech Se-adr | +1.4% | NEW | New buy |
| 5 | MDT | Medtronic plc | +1.4% | +26.43% | Add |
| 6 | BAX | Baxter International Inc | +1.2% | +48.08% | Add |
| 7 | BMY | Bristol-myers Squibb Co | +1.2% | +12.52% | Add |
| 8 | HUM | Humana Inc | +1.2% | NEW | New buy |
| 9 | CNC | Centene CORP | +1.1% | +111.11% | Add |
| 10 | CVS | Cvs Health CORP | +0.9% | +37.27% | Add |
| 11 | INCY | Incyte CORP | +0.6% | +27.35% | Add |
| 12 | BRKR | Bruker CORP | +0.6% | +37.67% | Add |
| 13 | LEGN | Legend Biotech Corp-adr | +0.6% | NEW | New buy |
| 14 | LNTH | Lantheus Holdings Inc | +0.1% | — | Unchanged |
| 15 | ZBH | Zimmer Biomet Holdings Inc | 0% | +24.71% | Add |
| 16 | GEHC | GE Healthcare Technology | 0% | +2.60% | Add |
| 17 | CAH | Cardinal Health Inc | — | +9.34% | Add |
| 18 | BIO | Bio-rad Laboratories-a | 0% | — | Unchanged |
| 19 | EW | Edwards Lifesciences CORP | -0.3% | +53.50% | Add |
| 20 | VTRS | Viatris Inc | -0.4% | EXIT | Sold out |
| 21 | IONS | Ionis Pharmaceuticals Inc | -0.5% | +24.02% | Add |
| 22 | ELV | Elevance Health Inc | -0.8% | +8.24% | Add |
| 23 | ALKS | Alkermes plc | -0.9% | -48.45% | Trim |
| 24 | AGIO | Agios Pharmaceuticals Inc | -1% | -44.27% | Trim |
| 25 | UHS | Universal Health Services-b | -1.2% | -49.64% | Trim |
| 26 | THC | Tenet Healthcare CORP | -1.3% | -50.13% | Trim |
| 27 | ALNY | Alnylam Pharmaceuticals Inc | -1.4% | EXIT | Sold out |
| 28 | BIIB | Biogen Inc | -1.7% | -20.05% | Trim |
| 29 | AMGN | Amgen Inc | -1.9% | -46.67% | Trim |
| 30 | PFE | Pfizer Inc | -2.2% | -8.38% | Trim |
| 31 | ABT | Abbott Laboratories | -2.7% | EXIT | Sold out |
| 32 | GILD | Gilead Sciences Inc | -3.4% | -31.18% | Trim |
According to official SEC Form 13F filings, Sector Gamma As reported a total U.S. public equity portfolio value of $461.0M across 29 disclosed positions in Q3 2024.
During Q3 2024, Sector Gamma As's top holdings by market value included BMY (9.4%)、MDT (9.2%)、GILD (7.4%). The largest single position, BMY, represented 9.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
BDX
市值: $18.6M
Top Position Liquidated / Trimmed
ABT
前期市值: $7.3M
In Q3 2024, Sector Gamma As made 30 total portfolio adjustments, initiating 4 new buys, adding to 15 positions, trimming 8 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.